All News
Filter News
Found 808,674 articles
-
Echosens Presents Symposium & Democenter at EASL International Liver Congress™ 2022: FibroScan® Solutions Bringing New Guidelines to Life, New FibroScan GO Demonstrations
6/21/2022
Echosens Presents Symposium & Democenter at EASL International Liver Congress™ 2022: FibroScan ® Solutions Bringing New Guidelines to Life, New FibroScan GO Demonstrations.
-
Carestream Shares Path to Accelerated Delivery of AI Features at HPE Discover 2022 Conference
6/21/2022
Carestream Health will share its path and commitment to delivering artificial-intelligence-powered features for medical imaging at the HPE Discover Edge-to-Cloud user conference June 28-30.
-
Jaguar Animal Health Exhibiting at the June 23-25 American College of Veterinary Internal Medicine (ACVIM) Forum as Part of Ongoing Commercial Launch Activities for Canalevia-CA1
6/21/2022
Jaguar Health, Inc. (NASDAQ:JAGX), under its Jaguar Animal Health tradename for the veterinary market, today announced that the company is exhibiting at the American College of Veterinary Internal Medicine (ACVIM) Forum, which takes place June 23 - 25, 2022 in Austin, TX.
-
Agenus to Host Investor Webcast to Review Late-Breaking Botensilimab and Balstilimab Data Presented at ESMO World GI Congress
6/21/2022
Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced the Company will host a hybrid webcast to discuss botensilimab/balstilimab combination data in microsatellite stable colorectal cancer (MSS-CRC).
-
Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 28, 2022
6/21/2022
Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced that it will issue financial results for its fiscal year ended March 31, 2022 , at 4:15 p.m. EST on Tuesday , June 28, 2022.
-
Cyclo Therapeutics to Present at the 2022 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation
6/21/2022
Presentation by Professor Caroline Hastings, MD, Chair of the Phase 3 Trappsol ® Cyclo™ Program Steering Committee and the Global Principal Investigator for the Company’s ongoing TransportNPC™ study evaluating Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C (NPC).
-
CareView Communications Selected to Exhibit Patient Safety System at Vizient Innovative Technology Exchange
6/21/2022
CareView Communications, Inc. ("CareView" or the "Company") (OTCQB: CRVW), an information technology provider to the healthcare industry, has been selected to exhibit the CareView Patient Safety System®, including its patented, predictive Virtual Bed Rails® and Virtual Chair Rails® technology, at the Vizient Innovative Technology Exchange.
-
Intercept Announces PBC Data Presentations at The International Liver Congress™ 2022
6/21/2022
Intercept Pharmaceuticals, Inc. today announced that multiple abstracts highlighting the benefits of obeticholic acid (OCA) in individuals with primary biliary cholangitis (PBC) will be presented at the International Liver Congress™ 2022, the 57th Annual Meeting of the European Association.
-
XORTX Announces “Fireside Chat” with XORTX CEO
6/21/2022
XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that on June 22, 2022 at 11am EST, Dr. Allen Davidoff, XORTX’s CEO, will host a “Fireside Chat” that will include a presentation “Exciting Developments in New Therapies for Progressive Kidney Diseases”.
-
Bausch Health Issues Form 8-K for 2022 Annual Meeting of Shareholders Presentation
6/21/2022
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced the Company is providing a presentation on its business during the Company's Annual Meeting of Shareholders on June 21, 2022.
-
Affinivax Presents Data for Enhanced Protection Against Serotype 3 in Next-Generation Pneumococcal Vaccine
6/21/2022
Preclinical data show synergistic protective effect of anti-protein and anti-polysaccharide antibodies in a highly virulent model of serotype 3 invasive pneumococcal disease.
-
Accolade to Announce Fiscal First Quarter 2023 Financial Results
6/21/2022
Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves over 600 employers and millions of members, today announced that it will release fiscal first quarter 2023 financial results on Thursday, June 30, 2022, after the market closes.
-
Arcellx Announces Closing of Upsized Public Offering of Common Stock and Underwriters' Full Exercise of Option to Purchase Additional Shares
6/21/2022
Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of its upsized public offering of 8,050,000 shares of common stock, which includes the full exercise by the underwriters of their option to purchase an additional 1,050,000 shares of common stock, at a price to the public of $16.00 per share.
-
Numinus to Participate in the H.C. Wainwright 1st Annual Mental Health Conference on June 27, 2022
6/21/2022
Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTC: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in the H.C. Wainwright 1st Annual Mental Health Conference to be held at the Lotte New York Palace Hotel in New York City on Monday, June 27, 2022.
-
Galectin Therapeutics Announces 2 Liver Cirrhosis Scientific Presentations at the EASL International Liver Congress™ 2022
6/21/2022
Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, announced today two scientific presentations regarding the use of artificial intelligence to analyze liver biopsies of patients affected with cirrhosis of the liver due to Nonalcoholic Steatohepatitis (NASH).
-
Precision BioSciences Announces $50 Million Offering of Common Stock
6/21/2022
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it has agreed to sell 35,971,224 shares of its common stock at a price of $1.39 per share, by way of an underwritten offering, for gross proceeds of approximately $50.0 million.
-
BetterLife To Present BETR-001 Preclinical Data at the Upcoming Federation of European Neuroscience Societies (FENS) Forum
6/21/2022
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, today announced that an abstract submitted on the anti-depressant activity of its lead compound 2-bromo-LSD (“BETR-001”) was accepted for poster presentation at the upcoming FENS Forum.
-
Quidel Corporation and the American Heart Association join forces to Advance Education and Awareness of Heart Disease in San Diego County
6/21/2022
QuidelOrtho announces that its subsidiary, Quidel Corporation, is collaborating with the American Heart Association, the leading voluntary health organization devoted to a world of longer and healthier lives, to improve the health of San Diego residents and deconstruct barriers to equitable health in our communities.
-
Protara Therapeutics Announces Departure of Chief Financial Officer
6/21/2022
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that Blaine Davis, Chief Financial Officer (CFO), has informed the Company that he will be leaving to pursue other opportunities.
-
Simulations Plus Sets Date for Third Quarter Fiscal Year 2022 Earnings Release and Conference Call
6/21/2022
Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report financial results for the third quarter of fiscal year 2022, the period ended May 31, 2022, after the close of the financial markets on Wednesday, July 6, 2022.b